HIV Infections Clinical Trial
Official title:
A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS
NCT number | NCT00000688 |
Other study ID # | ACTG 071 |
Secondary ID | RS-21592ICM 1697 |
Status | Completed |
Phase | Phase 3 |
First received | November 2, 1999 |
Last updated | March 11, 2011 |
To provide information about the usefulness and safety of giving injections of ganciclovir
(DHPG) for treating peripheral cytomegalovirus (CMV) retinitis.
CMV retinitis is an important sight-threatening opportunistic infection which affects 1 to 2
out of every 10 patients with AIDS. Results from an earlier study suggest that about 80
percent of patients with CMV retinitis will be helped by receiving intravenous doses of
DHPG.
Status | Completed |
Enrollment | 180 |
Est. completion date | |
Est. primary completion date | February 1995 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 13 Years and older |
Eligibility |
Inclusion Criteria Concurrent Medication: Allowed: - Zidovudine (AZT) for patients in delayed treatment group and not receiving ganciclovir. - Didanosine (ddI) may be continued or initiated in any patient during the study. - Topical acyclovir. - Topical ophthalmics. - Aerosolized pentamidine. Patients must have: - AIDS as defined by the CDC criteria or have had confirmation of HIV infection by ELISA, p24 antigen assay, or culture of HIV. - Retinal lesions greater than 1500 microns from edge of optic disc outside major temporal vascular arcades, and greater than 3000 microns from fovea. - Understanding of study provisions, and willingness to sign informed consent form approved by the appropriate Institutional Review Board and Syntex. - Life expectancy of at least 4 months. Exclusion Criteria Co-existing Condition: Patients with ocular conditions requiring immediate surgical correction are excluded. Concurrent Medication: Excluded during first 4 weeks of ganciclovir treatment: Zidovudine (AZT). Excluded: Other investigational drugs and antimetabolites, alkylating agents, nucleoside analogs (topical ophthalmics are permitted), acyclovir, interferon, foscarnet (non-nucleoside pyrophosphate analog), cytomegalovirus (CMV) hyperimmune globulin, and cytokines. Patients with the following are excluded: - Immediately sight-threatening retinitis (= or < 1500 microns from edge of optic disc, or inside major temporal vascular arcades, or = or < 3000 microns from the fovea). - Ocular media opacities (corneal, lenticular, or vitreal) preventing ophthalmologic and photographic retinal assessment. - Demonstrated hypersensitivity to acyclovir. Prior Medication: Excluded: - Previous treatment with anti-cytomegalovirus therapy. |
Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Univ of New Mexico Hlth Sciences Ctr / Dept of Med | Albuquerque | New Mexico |
United States | Infectious Disease Physicians Inc | Annandale | Virginia |
United States | Northwestern Univ Med School | Chicago | Illinois |
United States | Rush Presbyterian - Saint Luke's Med Ctr | Chicago | Illinois |
United States | Holmes Hosp / Univ of Cincinnati Med Ctr | Cincinnati | Ohio |
United States | Henry Ford Hosp | Detroit | Michigan |
United States | Univ TX Galveston Med Branch | Galveston | Texas |
United States | Infectious Diseases Association of Houston / Methodist Hosp | Houston | Texas |
United States | Plaza Med Ctr | Houston | Texas |
United States | Indiana Univ Hosp | Indianapolis | Indiana |
United States | Kansas City Veterans Administration Med Ctr | Kansas City | Missouri |
United States | Univ of Minnesota | Minneapolis | Minnesota |
United States | Cornell Univ Med Ctr | New York | New York |
United States | New York Univ Med Ctr / Dept of Environmental Med | New York | New York |
United States | Univ of California / San Diego Treatment Ctr | San Diego | California |
United States | Mount Zion Med Ctr | San Francisco | California |
United States | Pacific Presbyterian | San Francisco | California |
United States | Stanford at Kaiser / Kaiser Permanente Med Ctr | San Francisco | California |
United States | Mills Hosp | San Mateo | California |
United States | Washington Univ Med Ctr | St Louis | Missouri |
United States | Stanford Univ School of Medicine | Stanford | California |
United States | George Washington Univ Med Ctr | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) | Hoffmann-La Roche |
United States,
Spector SA, Weingeist T, Pollard RB, Dieterich DT, Samo T, Benson CA, Busch DF, Freeman WR, Montague P, Kaplan HJ, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group. J Infect Dis. 1993 Sep;168(3):557-63. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |